Samuraciclib trihydrochloride

Samuraciclib (CT7001) trihydrochloride is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib trihydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib trihydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib trihydrochloride has anti-tumor effects.

Product information

Molecular Weight: 503.90

Formula: C22H33Cl3N6O

Chemical Name: (3R, 4R)-4-(((7-(benzylamino)-3-isopropylpyrazolo[1, 5-a]pyrimidin-5-yl)amino)methyl)piperidin-3-ol trihydrochloride

Smiles: Cl.Cl.Cl.CC(C)C1C=NN2C=1N=C(C=C2NCC1=CC=CC=C1)NC[C@H]1CCNC[C@@H]1O

InChiKey: FWKOJLARRPFGOQ-QAZHXLKKSA-N

InChi: InChI=1S/C22H30N6O.3ClH/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29;;;/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27);3*1H/t17-,19+;;;/m1.../s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Samuraciclib trihydrochloride (ICEC0942; 0-10 µM; 24 hours; HCT116 cells) treatment promotes cell apoptosis. Samuraciclib trihydrochloride (ICEC0942; 0-10 µM; 24 hours; HCT116 cells) treatment induces cell cycle arrest. Samuraciclib trihydrochloride (ICEC0942; 0-10 µM; 0-24 hours; HCT116 cells) treatment inhibits the phosphorylation of PolII CTD in a dose and time dependent manner in HCT116 colon cancer cells. Samuraciclib trihydrochloride also inhibits phosphorylation of CDK1, CDK2 and retinoblastoma. Samuraciclib trihydrochloride (ICEC0942) inhibits the growth of MCF7, T47D, MDA-MB-231, HS578T, MDA-MB-468, MCF10A and HMEC cells with GI50 values of 0.18 µM, 0.32 µM, 0. 33 µM, 0.21 µM, 0.22 µM, 0.67 µM and 1.25 µM, respectively.

In Vivo:

Samuraciclib trihydrochloride (ICEC0942; 100 mg/kg; oral gavage; daily; for 14 days; female nu/nu-BALB/c athymic nude mice) treatment inhibits tumor growth by 60% at day 14, and is accompanied by highly significant reductions in PolII Ser2 and Ser5 phosphorylation in PBMCs and in tumors. The combination of Samuraciclib trihydrochloride (ICEC0942) and ICI 47699 treatment shows complete growth arrest of estrogen receptor (ER)-positive tumor xenografts.

Products are for research use only. Not for human use.